Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: A french prospective observational multicenter study

Surgical Infections

Volumn 10, Issue 2, 2009, Pages 119-127

  Gauzit, Rémy ^a   Péan, Yves ^b   Barth, Xavier ^c   Mistretta, Frédéric ^d   Lalaude, Olivier ^e  

^a HÔTEL DIEU   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d RCTS   (France)

^e Dohme Chibret Centre de Recherche Riom   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CARBAPENEM; CEPHALOSPORIN; IMIDAZOLE; LINCOSAMIDE; NITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; UREIDOPENICILLIN;

ABDOMINAL INFECTION; ADULT; ANTIMICROBIAL THERAPY; APPENDIX; ARTICLE; CLINICAL TRIAL; COLON; CONTROLLED STUDY; CULTURE TECHNIQUE; DEATH; DUODENUM; ENTEROCOCCUS; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; LAPAROSCOPY; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERCUTANEOUS DRAINAGE; PERITONEUM; PERITONITIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK; SCORING SYSTEM; SMALL INTESTINE; STOMACH; SURGICAL INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DATA INTERPRETATION, STATISTICAL; FEMALE; FRANCE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PERITONITIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 66249085209     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.092     Document Type: Article

References (35)

1. McClean KL, Sheehan GJ, Harding GK. Intraabdominal infection: A review. Clin Infect Dis 1994;19:100-116.
2. Montravers P, Chalfine A, Gauzit R, et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 2004;239:409-416.
3. Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: A multicenter randomized controlled trial. Antimi-crob Agents Chemother 2000;44:2028-2033.
4. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996;223:303-315.
5. Koperna T, Schulz F. Prognosis and treatment of peritonitis: Do we need new scoring systems? Arch Surg 1996;131:180-186.
6. Wittman DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg 1996;224:10-18.
7. Pitcher WD, Musher DM. Critical importance of early diagnosis and treatment of intra-abdominal infection. Arch Surg 1982;117:328-333.
8. Bosscha K, van Vroonhoven TJ, van der Werken C. Surgical management of severe secondary peritonitis. Br J Surg 1999;86:1371-1377.
9. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005.
10. Societe Francaise d'Anesthesie et de Reanimation. Management of community-acquired peritonitis-consensus conference-short text. Ann Fr Anesth Reanim 2001;20:368s-373s.
11. Davey P, Libby G, Hunter K, et al. How important is appropriate empirical antibiotic treatment for intra-abdominal infections? Value Health 2001;4:126-127.
12. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004;23:682-687.
13. Roehrborn A, Thomas L, Potreck O, et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001;33:1513-1519.
14. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963.
15. Cattan P, Yin DD, Sarfati E, et al. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 2002;21:787-793.
16. Sotto A, Lefrant JY, Fabbro-Peray P, et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrobial Chemother 2002;50:569-576.
17. Christou NV, Barie PS, Dellinger EP, et al. Surgical Infection Society intra-abdominal infection study: Prospective evaluation of management techniques and outcome. Arch Surg 1993;128:193-199.
18. Cometta A, Baumgartner JD. Treatment of severe infections: Should one always administer an aminoglycoside? Schweiz Med Wochenschr 1996;Suppl.76:28S- 33S.
19. Seiler CA, Brugger L, Forssmann U, et al. Conservative surgical treatment of diffuse peritonitis. Surgery 2000;127:178-184.
20. Carlet J. L'infection en reanimation. Masson Paris 1986; pp126-138.
21. Lau WY, Fan ST, Chu KW, et al. Influence of surgeons' experience on postoperative sepsis. Am J Surg 1988;155:322-326.
22. Bremmelgaard A, Raahave D, Beier-Holgersen R, et al. Computer-aided surveillance of surgical infections and identification of risk factors. J Hosp Infect 1989;13:1-18.
23. Haouet K, Kacem C, Kolsi K, et al. Facteurs de risque de l'in-fection des plaies operatoires en chirurgie digestive : Etude retrospective sur 3000 plaies operatoires. Tunis Med 2000; 78:634-640.
24. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543-549.
25. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of enterococcus in intraabdominal infection: Analysis of a prospective randomized trial. Surgery 1995;118:716-721.
26. Montravers P, Andremont L, Massias L, Carbon C. Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J Infect Dis 1994;169:821-830.
27. Sitges-Serra A, Lopez MJ, Girvent M, et al. Postoperative en-terococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002;89:361-367.
28. Christou NV, Turgeon P, Wassef R, et al. Management of intra-abdominal infections. Arch Surg 1996;131:1193-1201.
29. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenern/cilastin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990;212:581-591.
30. Bosscha K, Reijnders K, Hulstaert PF, et al. Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis. Br J Surg 1997;84:1532-1534.
31. Donahue PE, Smith DL, Yellin AE, et al. Trovafloxacin in the treatment of intra-abdominal infections: Results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. Am J Surg 1998;176(6A Suppl):53S-61S.
32. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997;132:1294-1302.
33. Huizinga WKJ, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995;36(Suppl A):179-189.
34. Dellinger EP, Wertz MJ, Meakins JL, et al. Surgical infection stratification system for intra-abdominal infection: Multi-center trial. Arch Surg 1985;120:21-29.
35. Solomkin JS, Hemsell DL, Sweet R, Tally F, Bartlett J. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15(Suppl 1):S33-S42.